RT Journal Article
SR Electronic
T1 Determining international spread of novel B.1.1.523 SARS-CoV-2 lineage
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.21.21266655
DO 10.1101/2021.11.21.21266655
A1 Zemaitis, Lukas
A1 Alzbutas, Gediminas
A1 Gecys, Dovydas
A1 Komissarov, Andrey
A1 Pautienius, Arnoldas
A1 Ugenskiene, Rasa
A1 Sukys, Marius
A1 Lesauskaite, Vaiva
YR 2021
UL http://medrxiv.org/content/early/2021/11/24/2021.11.21.21266655.abstract
AB Here we report the emergence of variant lineage B.1.1.523 that contains a set of mutations including 156_158del, E484K and S494P in Spike protein. E484K and S494P are known to significantly reduce SARS-CoV-2 neutralization by convalescent and vaccinee sera and are considered as mutations of concern. Lineage B.1.1.523 has presumably originated in Russian Federation and spread across European countries with the peak of transmission in April – May 2021. The B.1.1.523 lineage has now been reported from 27 countries.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by Ministry of Health of The Republic of Lithuania Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study involves only openly available human data, which can be obtained from https://www.gisaid.orgI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript